Piramal Pharma Solutions Installs 4.3 MW Solar Plant at UK Site to Cut Emissions — Piramal Pharma Solutions

Event summary

Piramal Pharma Solutions is adding a 4.3 MWp ground-mounted solar power plant at its Morpeth, UK site.
The plant will generate ~3,950 MWh of renewable electricity annually, covering 22% of the site's electricity demand.
The project, under a Power Purchase Agreement with Alight, aims to avoid ~20,000 tCO₂e over 25 years.
Operations are scheduled to begin in Q1 2027.

The big picture

Piramal's solar plant installation aligns with broader industry trends toward decarbonization and energy independence in pharmaceutical manufacturing. The move reflects growing pressure on CDMOs to reduce Scope 1 and 2 emissions while managing long-term energy costs. The project's scale—covering 22% of the site's electricity needs—positions Piramal as a leader in sustainable operations within the contract development space.

What we're watching

Execution Risk: Whether Piramal can meet its 42% emissions reduction target by FY2030 with this and similar initiatives.
Cost Efficiency: How the solar plant's operational costs compare to traditional energy sources over its lifespan.
Regulatory Compliance: The pace at which UK regulations may further incentivize or mandate such renewable energy projects in the pharmaceutical sector.